Trial Profile
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Aug 2022
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Dry age-related macular degeneration; Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms PREVENT
- 23 Aug 2022 Status changed from recruiting to completed.
- 01 Aug 2016 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.
- 01 Aug 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2018.